ATLASATLAS fair value
ATLAS has no fair value for this stock today.
TriSalus Life Sciences (TLSI)
TriSalus Life Sciences stock price today, ATLAS forecast and fair value
Healthcare · Medical Devices · NASDAQ
$3.80▲ +4.97%
Prices as of Oct 27, 2026 · USD
Chance of rising in 1 month
48%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on TriSalus Life Sciences in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On TriSalus Life Sciences
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives TriSalus Life Sciences a 48% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between $3.47 and $4.13; in 9 out of 10, between $2.97 and $4.81. Estimated annual volatility is 49%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- $266M
- 52-week high
- $7.95
- 52-week low
- $2.20
- Revenue (12 months)
- $45.1M
- Revenue growth (YoY)
- +53.4%
- Gross margin
- 84.6%
- Operating margin
- -59.7%
- Net margin
- -86.9%
- Return on equity
- 205.8%
- Free cash flow (12 months)
- $-10.9M
- Beta
- 0.44
What this means
ATLAS does not publish a fair value for TLSI right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks TLSI has traded between $2.20 and $7.95. Today it is 52.2% below that high and 73% above its low.
On the business: revenue grew 53.4% year over year; net margin is 86.9%.
Its beta is 0.44: it tends to move less than the market.
About the company
TriSalus Life Sciences, Inc. is an oncology-focused medical technology company developing drug delivery systems and immuno-oncology therapies for difficult-to-treat liver and pancreatic cancers.
Want to see everything about TriSalus Life Sciences?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does TriSalus Life Sciences do?
TriSalus Life Sciences, Inc. is an oncology-focused medical technology company developing drug delivery systems and immuno-oncology therapies for difficult-to-treat liver and pancreatic cancers.
What is the chance TLSI goes up next month?
48%: close to a coin flip. In half of the simulated outcomes, TLSI ends the month between $3.47 and $4.13.
How big is TriSalus Life Sciences and what is its P/E ratio?
TriSalus Life Sciences's market capitalization is $266M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is TLSI?
ATLAS estimates annual volatility at 49%. In a typical month, half of the outcomes end between $3.47 and $4.13.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer